Bio-Sell Biotech Secures Nearly RMB 100 Million in Series Financing Led by China Health Capital

VCBeat has learned that Shanghai Bioscience Co., Ltd. (“Bioscience”) recently announced the completion of a new round of financing amounting to nearly RMB 100 million, with Huagai Capital as the sole investor. The proceeds from this round will be used to accelerate the development of its proprietary brand product portfolio through mergers and acquisitions as well as in-house development, build a modernized supply chain system, and strengthen its digital e-commerce platform, thereby comprehensively enhancing its capacity to serve global customers.

Mr. Liu Pei, Chairman of Shanghai Bioscience Co.,Ltd.“The trust and support from Huagai Capital are a great honor for us. The success of this financing round marks another recognition by the capital market of Shanghai Bioscience Co.,Ltd.'s strength in the life sciences services sector. Looking ahead, we will focus on cutting-edge technologies and continue to increase our R&D investment; enhance our product development and lean manufacturing capabilities to promote the growth of our proprietary brands; and further diversify our business ecosystem. Working hand in hand with our supplier partners, we aim to deliver more efficient and professional solutions to our customers, thereby fostering innovation and development in the life sciences field.”

Mr. Xu Xiaolin, Chairman of Huagai Capitalstated: “Adhering to its mission of ‘Serving Science,’ Shanghai Bioscience has established an exceptional business model in the life sciences services sector and continues to expand its business scale. With an outstanding strategy and execution team, Shanghai Bioscience has built a globally leading one-stop service platform, a robust supply chain system, and a product portfolio that is constantly innovating and upgrading. These strengths have enabled Shanghai Bioscience to stand out in today’s highly competitive market. We highly recognize Shanghai Bioscience’s development potential and look forward to injecting capital and resources to help it become a leading enterprise in China’s life sciences services sector.”

Shanghai Bioscience Co., Ltd. was established in 2005 and is a platform-based service provider specializing in the life sciences sector. The company serves over 60,000 group clients, employs more than 600 staff members, operates 26 offices/branches, and offers millions of products. Guided by its mission of “Serving Science,” Shanghai Bioscience has built a multi-dimensional product portfolio tailored to the needs of diverse research and production scenarios. It has established strategic partnerships with globally renowned companies such as Takara Bio, Corning, Danaher, and Thermo Fisher Scientific, while maintaining close collaborations with more than 20 leading life science brands in the industry, thereby empowering researchers to achieve greater advancements in their exploration of life sciences.

Bioscience Select is the umbrella brand for Shanghai Bioscience Co., Ltd.’s proprietary product lines, encompassing four major categories: laboratory instruments, consumables, reagents, and technical services. Upholding Bioscience’s longstanding commitment to innovation and focus, Bioscience Select leverages its in-house technology center and production supply chain system to deliver high-quality, one-stop laboratory solutions to life science researchers worldwide.

Huagai Capital, established in 2012, is a private equity investment firm co-founded by professionals from leading investment institutions and industry experts. With the vision of “becoming the most trusted capital partner for entrepreneurs and investors,” the company focuses on private equity investments in the healthcare and technology sectors, committed to fostering the growth of small and medium-sized enterprises into industry leaders. Currently, Huagai Capital manages approximately RMB 26 billion in assets, has supported the development of over 160 companies, and facilitated the public listing of 26 of them.